Key result
2D echocardiography underestimates LVEF vs CMR, leading to cardiotoxicity misclassification in ~9% of patients.
Why the study?
To compare LVEF measured with echocardiography and cardiac MRI in individuals with cancer and suspected cardiotoxicity, and assess the potential effect on downstream clinical decision-making.
Does echocardiography accurately measure LVEF compared to cardiac MRI in individuals with cancer and suspected cardiotoxicity?
Observational (n=745)
None
No
Does echocardiography accurately measure LVEF compared to cardiac MRI in individuals with cancer and suspected cardiotoxicity?
2D echocardiography has significant variation compared to cardiac MRI for LVEF measurement in cancer patients, leading to misclassification of cardiotoxicity, whereas 3D echocardiography shows better agreement.
Answers are grounded in this paper and cite their sources.
May result in cardiotoxicity misclassification with 2D echocardiography; leaves open CMR's role for accurate monitoring in cancer patients.
Purpose To compare left ventricular ejection fraction (LVEF) measured with echocardiography and cardiac MRI in individuals with cancer and suspected cardiotoxicity and assess the potential effect on downstream clinical decision-making. Materials and Methods In this prospective, single-center observational cohort study, participants underwent same-day two-dimensional (2D) echocardiography and cardiac MRI between 2011 and 2021. Participants with suboptimal image quality were excluded. A subset of 74 participants also underwent three-dimensional (3D) echocardiography. The agreement of LVEF derived from each modality was assessed using Bland-Altman analysis and at relevant thresholds for cardiotoxicity. Results A total of 745 participants (mean age, 60 years ± 5 [SD]; 460 [61.7%] female participants) underwent same-day echocardiography and cardiac MRI. According to Bland-Altman analysis, the mean bias was –3.7% ± 7.6 (95% limits of agreement [LOA]: –18.5% to 11.1%) for 2D echocardiography versus cardiac MRI. In 74 participants who underwent cardiac MRI, 3D echocardiography, and 2D echocardiography, the mean LVEFs were 60.0% ± 10.4, 58.4% ± 9.4, and 57.2% ± 8.9, respectively (P < .001). At the 50% LVEF threshold for detection of cardiotoxicity, there was disagreement for 9.3% of participants with 2D echocardiography and cardiac MRI. Agreement was better with 3D echocardiography and cardiac MRI (mean bias, –1.6% ± 6.3 [95% LOA: –13.9% to 10.7%]) compared with 2D echocardiography and cardiac MRI (mean bias, –2.8% ± 6.3 [95% LOA: –15.2% to 9.6%]; P = .016). Conclusion Two-dimensional echocardiography had variations of ±15% for LVEF measurement compared with cardiac MRI in participants with cancer and led to misclassification of approximately 10% of participants for cardiotoxicity detection. Three-dimensional echocardiography had better agreement with cardiac MRI and should be used as first-line imaging. Keywords: Echocardiography, MR Functional Imaging, Cardiac Supplemental material is available for this article.
No takes yet. Share an insight, caveat, or question.
Nazir et al. (2024) conducted an observational in Cancer with suspected cardiotoxicity (n=745). 2D echocardiography vs. Cardiovascular Magnetic Resonance (CMR) was evaluated on Left ventricular ejection fraction (LVEF) median percentage (Mean bias -3.7%, 95% CI -18.5 to 11.1, p=<0.001). 2D echocardiography underestimated left ventricular ejection fraction with a mean bias of -3.7% compared to CMR, leading to cardiotoxicity misclassification in 9.1% of patients.
Synapse has enriched 10 related papers. Consider them for comparative context: